News
10-03-2012, 02:13 AM
Data from the Phase III EMILIA study, presented at the European Society for Medical Oncology (ESMO) show that T-DM1 (trastuzumab emtansine) prolongs the lives of patients with advanced HER2-positive breast cancer when compared with the only approved licensed treatment combination, lapatinib and capecitabine, (30.9 months vs. 25.1 months, HR=0.682; P=0...
More... (http://www.medicalnewstoday.com/releases/251007.php)
More... (http://www.medicalnewstoday.com/releases/251007.php)